Abstract
Background: USP7 (ubiquitin specific protease 7, also known as HAUSP) is one of the deubiquitinating enzymes (DUB) that reverses ubiquitination and spares substrate proteins from degradation.
Methods: After a brief introduction of ubiquitin-proteasome system (UPS) and human DUB, this review focuses on the structural and functional complexity of USP7 in tumor development and progression. Afterwards, physiological regulatory mechanisms and manipulation strategies for USP7 are elaborated. Finally, we discuss the advances and difficulties of USP7 as a novel therapeutic target for cancer.
Results: It is mostly concerned that USP7 regulates the dynamics of the p53 and Mdm2 network by deubiquitinating both p53 and its E3 ubiquitin ligase, Mdm2. Recently, USP7 has also been recognized as a regulator of many other tumor associated proteins such as FOXO, PTEN and Claspin, consequently being involved in cell cycle control, DNA damage response, apoptosis and many other cellular processes. Consistently, aberrant USP7 expression and activity have been connected to various types of cancers, which along with lots of validating genetic and functional experiments make this enzyme a compelling target for the treatment of cancer. Currently disclosed inhibitor discovery programs and relevant research have identified several synthetic small molecules, natural compounds, small peptides and one ubiquitin variant that have specific USP7 inhibitory effects and considerable antitumor activities.
Conclusion: Taken together, USP7 is a promising therapeutic target and USP7 inhibitors hold promise as a new approach to cancer therapy.
Keywords: Apoptosis, cancer therapy, deubiquitinase, target validation, USP7, USP7 inhibitors.
Graphical Abstract
Medicinal Chemistry
Title:USP7: Target Validation and Drug Discovery for Cancer Therapy
Volume: 14 Issue: 1
Author(s): Jin Zhou*, Jinzheng Wang, Chao Chen, Haoliang Yuan, Xiaoan Wen*Hongbin Sun*
Affiliation:
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009,China
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009,China
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009,China
Keywords: Apoptosis, cancer therapy, deubiquitinase, target validation, USP7, USP7 inhibitors.
Abstract: Background: USP7 (ubiquitin specific protease 7, also known as HAUSP) is one of the deubiquitinating enzymes (DUB) that reverses ubiquitination and spares substrate proteins from degradation.
Methods: After a brief introduction of ubiquitin-proteasome system (UPS) and human DUB, this review focuses on the structural and functional complexity of USP7 in tumor development and progression. Afterwards, physiological regulatory mechanisms and manipulation strategies for USP7 are elaborated. Finally, we discuss the advances and difficulties of USP7 as a novel therapeutic target for cancer.
Results: It is mostly concerned that USP7 regulates the dynamics of the p53 and Mdm2 network by deubiquitinating both p53 and its E3 ubiquitin ligase, Mdm2. Recently, USP7 has also been recognized as a regulator of many other tumor associated proteins such as FOXO, PTEN and Claspin, consequently being involved in cell cycle control, DNA damage response, apoptosis and many other cellular processes. Consistently, aberrant USP7 expression and activity have been connected to various types of cancers, which along with lots of validating genetic and functional experiments make this enzyme a compelling target for the treatment of cancer. Currently disclosed inhibitor discovery programs and relevant research have identified several synthetic small molecules, natural compounds, small peptides and one ubiquitin variant that have specific USP7 inhibitory effects and considerable antitumor activities.
Conclusion: Taken together, USP7 is a promising therapeutic target and USP7 inhibitors hold promise as a new approach to cancer therapy.
Export Options
About this article
Cite this article as:
Zhou Jin *, Wang Jinzheng , Chen Chao , Yuan Haoliang , Wen Xiaoan*, Sun Hongbin *, USP7: Target Validation and Drug Discovery for Cancer Therapy, Medicinal Chemistry 2018; 14 (1) . https://dx.doi.org/10.2174/1573406413666171020115539
DOI https://dx.doi.org/10.2174/1573406413666171020115539 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in Boron Neutron Capture Therapy (BNCT) Driven by Nanotechnology
Current Chemical Biology Enhancing Nucleic Acid Delivery, Insights from the Cationic Phospholipid Carriers
Current Pharmaceutical Biotechnology Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders
Current Rheumatology Reviews Gold - Old Drug with New Potentials
Current Medicinal Chemistry Discovery of Novel NAMPT Inhibitors Based on Pharmacophore Modeling and Virtual Screening Techniques
Combinatorial Chemistry & High Throughput Screening Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Controlled Releases of FGF-2 and Paclitaxel from Chitosan Hydrogels and their Subsequent Effects on Wound Repair, Angiogenesis, and Tumor Growth
Current Drug Delivery Development ofNovel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions
Endocrine, Metabolic & Immune Disorders - Drug Targets Aerosol Therapy for Malignancy Involving the Lungs
Current Cancer Drug Targets Feasibility of Increased Navy Bean Powder Consumption for Primary and Secondary Colorectal Cancer Prevention
Current Nutrition & Food Science Synthesis, Anticancer Screening and Molecular Docking Studies of New Heterocycles with Trimethoxyphenyl Scaffold as Combretastatin Analogues
Mini-Reviews in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Chemical Diversity of Bioactive Marine Natural Products: An Illustrative Case Study
Current Medicinal Chemistry Preface
Anti-Cancer Agents in Medicinal Chemistry Non-Classical Structures Among Current Platinum Complexes with Potential as Antitumor Drugs
Current Topics in Medicinal Chemistry Cascade Reaction in the Synthesis of Heterocyclic Natural Products
Current Organic Chemistry Targeting Cell Cycle to Suppress Cancer Aggressiveness
Current Signal Transduction Therapy Design, Synthesis and Anticancer Evaluation of Carbazole Fused Aminopyrimidine Derivatives
Letters in Organic Chemistry Anticancer Activity of 5-Benzylidene-2-Phenylimino-1, 3-Thiazolidin-4-one (BPT) Analogs
Medicinal Chemistry